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Late Effects of Intracoronary Streptokinase on Regional Wall Motion,
Ventricular Aneurysm and Left Ventricular Thrombus in Myocardial
Infarction: Results From the Western Washington Randomized Trial
JOHN R. STRATTON, MD, FACC, SARAH M. SPECK, MD, JAMES H. CALDWELL, MD,
MICHAEL L. STADIUS, MD, CHARLES MAYNARD, MA, KATHRYN B. DAVIS, PHD,
JAMES L. RITCHIE, MD, FACC, J. WARD KENNEDY, MD, FACC
Seattle, Washi/l!?ton
To determine whether intracoronary streptokinase im-
proves late regional wall motion or reduces left ventric-
ular aneurysm or thrombus formation in patients with
acute myocardial infarction, two-dimensionalechocardi-
ography was performed at 8 ± 3 weeks after infarction
in 83 patients randomized to streptokinase (n = 45) or
standard therapy (n = 38) in the Western Washington
Intracoronary Streptokinase Trial. Among the patients
treated with streptokinase, the average time to treatment
was 4.7 ± 2.5 hours after the onset of chest pain, and
67% had successful reperfusion. Regional wall motion
was assessed in nine left ventricular segments on a scale
of I to 4 (normal, hypokinetic, akinetic and dyskinetic).
Left ventricular thrombus formation was interpreted as
positive, equivocal or negative. All patients received an-
ticoagulant therapy in the hospital and 52 received such
therapy after hospital discharge.
The mean (± SD) global (1.5 ± 0.4 in both groups)
Intracoronary streptokinase reestablishes coronary artery pa-
tency in 60 to 80% of patients with acute myocardial in-
farction (1-12). However, it has not been conclusively de-
termined whether reestablishment of flow in the obstructed
artery can be accomplished sufficiently rapidly in the clinical
setting to preserve left ventricular function in most patients
with acute infarction. Although results from nonrandomized
studies have suggested improvement in left ventricular func-
tion measured by a variety of techniques in patients treated
with streptokinase (2,6-1 I.I 3,14), randomized trials
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and regional wall motion scores in the streptokinase-
treated and control groups were not significantly differ-
ent. The prevalenceofaneurysm was 16% in both groups.
Left ventricular thrombus was identified in only five
patients (positive identification in four, and equivocal in
one), all in the streptokinase-treated group (p = NS).
There were also no differences between streptokinase
and control treatment in any of the echocardiographic
variables in subgroups of patients with anterior infarc-
tion, inferior infarction, no prior infarction or reper-
fusion with streptokinase.
It is concluded that intracoronary streptokinase given
relatively late in the course of acute myocardial infarc-
tion does not result in improved global or regional wall
motion or a reduction in left ventricular thrombus or
aneurysm formation in survivors studied 2 months after
myocardial infarction.
(J Am Coli CardioI1985;5:1023-8)
(3,15-17), with one exception (4), have failed to demon-
strate a benefit from streptokinase therapy. One reason that
such trials may have failed to detect an improvement in left
ventricular function is that most trials assessed only global
left ventricular function by contrast angiography or radio-
nuclide techniques. This applies to our previous study (15)
based on global and regional ejection fraction. However, it
may be necessary to measure localized wall motion changes
to adequately evaluate the effects of an intervention designed
to improve left ventricular function in the ischemic zone
(10). Additionally, most studies that have evaluated the
effects of intracoronary streptokinase on left ventricular
function have assessed changes early after therapy. There
are limited data regarding the longer-term effects of intra-
coronary streptokinase. Left ventricular aneurysm and left
ventricular thrombus formation occur relatively commonly,
particularly in patients with transmural anterior myocardial
infarctions. Whether intracoronary streptokinase reduces these
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Figure 1. Schematic diagrams showing the nine left ventricular
segments analyzed by two-dimensional echocardiography. The an-
teroseptal wall comprised segments I, 2; 3 and 4, the inferopos-
terior wall 5 and 6, the lateral wall 7 and 8 and the apex 9. Ao
= aorta; LA = left atrium; LV left ventricle; RA = right
atrium; RV = right ventricle.
trol). Of the 85 echocardiographic studies, 2 were techni-
cally inadequate (both from patients in the streptokinase-
treated group), and these patients are excluded from further
analysis. Thus, echocardiographic and clinical data are re-
ported on 83 randomized patients who were studied 8 ± 3
weeks (± I SD) after randomization. Of these 83 patients,
6 were studied at 0 to 28 days after myocardial infarction,
48 at 29 to 56 days, 19 at 57 to 84 days, 9 at 85 to 112
days and I patient at 129 days.
Two-dimensional echocardiography. Two-dimen-
sional echocardiography was performed in a single core
laboratory using a wide-angle phased array sector scanner
(Toshiba Medical Systems). Conventional parasternal long-
axis and short-axis and apical two and four chamber views
were obtained on all subjects. To examine thoroughly for
apical thrombus formation, we also acquired additional peri-
apical views as previously described (19). Echocardiograms
were reviewed twice by two observers who had no knowl-
edge of patient data.
Regional wall motion. This was evaluated in nine seg-
ments as described by Heger et al. (20) (Fig. 1). On a
technically good study, all segments were seen in at least
two views. Segments not visualized in any view because of
technical limitations were not graded. The anteroseptal wall
contained four segments (segments 1,2,3 and 4), the infer-
oposterior wall contained two (segments 5,6), the lateral
wall contained two (segments 7,8) and the apex contained
~\~
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Methods
complications of myocardial infarction has not been deter-
mined in a randomized trial.
The Western Washington Intracoronary Streptokinase Trial
randomly assigned patients with acute myocardial infarction
and evidence of coronary artery thrombi on acute angiog-
raphy to either intracoronary streptokinase therapy or to
standard therapy (I). The purpose of this study was to de-
termine whether intracoronary streptokinase caused an im-
provement in echocardiographically defined global or re-
gional wall motion or a reduction in left ventricular thrombus
or aneurysm formation at I to 2 months after acute myo-
cardial infarction.
Studyprotocol. The Western Washington Randomized
Streptokinase Trial was a multicenter study involving 14
hospitals. The primary goal of the trial was to deterrriine
whether intracoronary administration of streptokinase de-
creased mortality inpatients with acute myocardial infarc-
tion. Patients younger than 75 years of age whose symptoms
of acute myocardial infarction had begun less than 12 hours
before cardiac catheterziation and who had typical electro-
cardiographic changes (ST elevation in more than two leads
or marked T wave changes) were eligible. Patient selection,
randomization and management have been previously de-
scribed in detail (l, 18). At the time of cardiac catheteriza-
tion, patients with thrombotic obstruction (total or subtotal)
of a coronary artery that was not responsive to intracoronary
nitroglycerin therapy were randomized to receive either
intracoronary streptokinase or conventional therapy. After
randomization, control patients returned to the coronary care
unit, and patients treated with streptokinase immediately
received intracoronary streptokinase at a rate of 4,000
units/min.. The infusion was continued until one-half hour
after reperfusion occurred or to a total of 250,000 to 300,000
units. All patients (streptokinase-treated and control) re-
ceived anticoagulant therapy with heparin and then warfarin
until hospital discharge and it was suggested, but not re-
quired, that patients be maintained on warfarin therapy for
3 months.
Patients. For determination of the late effects of strep-
tokinase on echocardiographically defined regional wall mo-
tion and aneurysm and thrombus, we studied patients en-
tered during the first 9 months of the Western Washington
Randomized Trial in a single echocardiographic laboratory.
(Resources for studying patients after that time were not
available). During the first 9 months of the trial, 126 patients
were entered. Thirteen patients (3 streptokinase-treated, 10
control) died before 30 days. Of the remaining 113 con-
secutive 30 day survivors, we studied 85 (75%). Twenty-
eight patients were hot studied with echocardiography be-
cauSe of coronary artery bypass grafting (2 streptokinase-
treated, 5 control), interval infarction (l streptokinase-treated,
ocontrol) or patient refusal (9 streptokinase-treated, II con-
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'All statistical comparisons were nonsignificant (p > 0.05).
Table 2. Echocardiographic Regional Wall Motion Scores
Mean (±SD)*
randomization. Patients treated with streptokinase had a
slightly greater prevalence of anterior infarction than did
control patients, but this difference was not statistically sig-
nificant (p = 0.13). Patients treated with streptokinase re-
ceived a mean of 280,954 ± 73,217 units of streptokinase
beginning 4.7 ± 2.5 hours after the onset of symptoms,
and in 67% reperfusion occurred at a mean of 6.1 ± 2.6
hours after the onset of symptoms.
Anticoagulant therapy was discontinued in 24 patients
(10 streptokinase-treated, 14 control) during their hospital-
ization after a mean of 1.4 ± 0.9 weeks. In 43 patients (23
streptokinase-treated, 20 control), anticoagulant therapywas
discontinued after hospitalization at a mean of 9.0 ± 8.0
weeks. Ten patients continued anticoagulant therapy indef-
initely (eight streptokinase-treated, two control), and six
patients (four streptokinase-treated, two control) had un-
known anticoagulant status. Platelet inhibitory agents (as-
pirin, dipyridamole, sulfinpyrazone or aspirin plus dipyri-
damole) were prescribed for 12patients in the streptokinase-
treated and 9 patients in the control group.
Echocardiographic results. There were no significant
differences between control patients and patients treated
with streptokinase in regional wall motion in any of the nine
individual segments. Likewise, when regions were summed
into the anteroseptal wall, inferoposterior wall, lateral wall
or the apex, there were also no significantdifferences (Table
2). There was a tendency for patients treated with strepto-
kinase to have slightly worse apical wall motion than that
of control patients (2.0 ± 1.2 versus 1.7 ± 1.0, P = 0.07)
because of the greater prevalence of anterior infarction in
Table l. Patient Characteristics*
58 ± 9
35/3
7
Control
(n = 38)
10
28
130 ± 103
271 ± 126
76%
58 ± 9
40/5
4
19
26
143 ± 145
280 ± 151
89%
Streptokinase-treated
(n = 45)
Age (yr)
Sex (M/F)
History of prior myocardial
infarction
Acute anterior infarction
Acute inferior infarction
Time to admission (min)
Time to randomization (min)
Percent with total occlusion
one (segment 9). Wall motion in each segment was graded
on a scale of 1 to 4 (I = normal, 2 = hypokinetic, 3 =
akinetic and 4 = dyskinetic). For an assessment of global
ventricular function, a global wall motion index was cal-
culated by summing the scores for each segment and di-
viding by the number of segments analyzed. Similar mean
regional wall motion scores were calculated for the anter-
oseptal wall, the inferoposterior wall, the lateral wall and
the apex. In each case, a normal global or regional score
was I, and the worst possible score was 4.
Reproducibility. Disagreements between observers oc-
curred in 11.6% (87 of 747) of the segments and were
resolved by consensus after repeat viewing of the study. In
94% (82 of 87) of the disagreements, the observers differed
by only one wall motion class. In the remaining five in-
stances, they disagreed by two classes. To determine the
reproducibilityof the consensus reading of the regional wall
motion analysis, 12 studies with a total of 108 segments
were analyzed 2 months apart. The consensus reading was
the same in 89% (96 of 108) of the segments and differed
by one class in 10 segments and by two classes in 2 seg-
ments. Thus. the method of regional wall motion analysis
was considered reproducible.
Left ventricular aneurysm and thrombus. An aneurysm
was defined as a localized area of akinesia or dyskinesia
that deformed the ventricular chamber during both diastole
and systole (21). An area that was dyskinetic in systole but
did not have an associated diastolic contour abnormality
was not considered an aneurysm. Left ventricular thrombus
was defined as a discrete mass of echoes in the left ventricle
that was distinct from the endocardium, seen in both systole
and diastole, located in an area of asynergy (hypokinetic,
akinetic or dyskinetic), and identified inat least two different
views. These criteria have been previously validated in our
laboratory; when equivocal echocardiographic studies are
considered negative, the sensitivity is 86% and the speci-
ficity 95% for the detection of thrombus formation (19).
Statistical analysis. The chi-square analysis and t test
were used to compare the distribution of discrete variables
between groups. Thirteen patients were not studied by echo-
cardiography because they died before their scheduled ap-
pointment (3 streptokinase-treated, 10 control). To assess
the potential effects of these patients on the cchocardio-
graphic findings, we performed a second analysis using a
nonparametric test (Wilcoxon rank sum test), with the pa-
tients who died assigned the worst rank (4 = dyskinetic)
for all segments. All data are expressed as the mean ±
standard deviation.
Results
Patient characteristics (Table 1). There were no sig-
nificant differences between streptokinase-treated and con-
trol groups inage, sex distribution, historyof prior infarction
or time from the onset of chest pain to hospitalization or to
Antero- Infero-
septal posterior Lateral Apex Global
Streptokinase-treated 16 1.7 10 2.0 1.5
patients (n = 45) ± 0.7 ± 0.8 ± 03 ± 1.2 ± 0.4
Control patients 1.5 1.7 II 1.7 1.5
(n = 38) ± 0.7 ± 0.8 .!- 0.2 ± 1.0 ± 0.4
'All probability values arc not significantbetween streptokinase-treated
and control groups.
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the streptokinase-treated group. The mean global wall mo-
tion index was identical in the two groups (1.5 ± 0.4).
A left ventricular aneurysm occurred in 7 (16%) of 45
patients treated with streptokinase and in 6 (16%) of 38
control patients. Left ventricular thrombus formation was
uncommon. There were four definite thrombi and one equiv-
ocal thrombus. All occurred in patients treated with strep-
tokinase with anterior infarction (p = NS versus control
patients). Three of the patients with ventricular thrombus
had reperfusion with streptokinase and two did not. Two of
the patients had an associated apical aneurysm and three did
not. The duration of anticoagulant treatment was unknown
in one patient, was 2 days in one patient and 3 weeks in
the remaining three patients.
There was no benefit ofstreptokinase therapy on regional
wall motion or aneurysm or thrombus formation in subgroups
of patients with the following characteristics: 1) anterior
myocardial infarction (19 streptokinase-treated patients, 10
control patients); 2) inferior myocardial infarction (26 strep-
tokinase-treated, 28 control); 3) no prior myocardial in-
farction (41 streptokinase-treated, 31 control); 4) random-
ization less than 3 hours from the onset of symptoms (9
streptokinase-treated, 8 control); or 5) randomization more
than 3 hours from the onset of symptoms (36 streptokinase-
treated, 30 control). There was also no benefit in patients
treated with streptokinase who had reperfusion induced by
therapy (n = 30) compared with either patients treated with
streptokinase without reperfusion (n = 15) or with control
patients (n = 38).
Since there were more early deaths «30 days) in the
control group (n = 10) than in the streptokinase-treated
group (n = 3), the data were reanalyzed classifying those
deaths to the worst rank for regional wall motion. In these
analyses, there was still no significant benefit associated
with streptokinase therapy when the treated and control groups
were compared in relation to anteroseptal, inferoposterior,
lateral, apical or global wall motion scores.
Discussion
The results of this study indicate that intracoronary strep-
tokinase therapy, when instituted at a mean of 4.7 hours
after the onset of symptoms, does not lead to improved
regional wall motion or result in a decreased incidence of
left ventricular aneurysm or left ventricular thrombus for-
mation in late survivors after acute myocardial infarction.
Left ventricular function after intracoronary strep-
tokinase. This study differs from most prior studies that
have assessed regional or global function after streptokinase
therapy in that we examined patients relatively late after
infarction. Our study documents that any early improvement
caused by streptokinase therapy in regional or global left
ventricular function was not sustained at 8 weeks after in-
farction. Our findings in this randomized trial contrast with
the results of Smalling et al. (8), who found, in a nonran-
domized trial, sustained improvement in global radionuclide
ejection fraction in 45 patients treated with streptokinase at
6 months. Similarly, Rentrop et al. (14), in a retrospective,
nonrandomized trial, found sustained benefit in 24 patients
treated with streptokinase compared with 21 control patients
studied by contrast angiography at 1 to 2 months after in-
farction, in terms of both global ejection fraction and the
percent of noncontracting segments. Sheehan et al. (10), in
another nonrandomized study, found that patients with re-
perfusion failed to have a significant increase in global ejec-
tion fraction from early to late studies, but did show im-
provement in regional wall motion in initially hypokinetic
areas.
Among randomized trials, only the study of Anderson et
al. (4), using echocardiography and radionuclide ventricu-
lography, suggested an early improvement in pump function
in patients who were treated with streptokinase at a mean
of 4 hours after the onset of symptoms, while three other
randomized studies (3,16,17) failed to show improvement
in ventricular performance within the first 1 to 2 weeks after
therapy.
Limitations. Visual assessment of two-dimensional
echocardiograms, the method utilized to assess regional and
global ventricular function in this study, clearly has limi-
tations. The imaging protocol was designed to allow visu-
alization of all nine myocardial regions in at least two dif-
ferent views. Occasionally, however, an individual segment
was clearly visible in only one view. In two patients, studies
were technically inadequate to assess wall motion, and these
patients were excluded from analysis. It is possible that our
qualitative technique of assessing pump function was in-
sensitive to small changes; however, changes too small for
the resolution of the technique are unlikely to be of clinical
significance.
One limitation of this study is that preintervention echo-
cardiograms were not obtained, and an even distribution of
wall motion abnormalities before therapy cannot be as-
sumed. However, analysis of the 72 patients (41 strepto-
kinase-treated, 31 control) with no prior history of myo-
cardial infarctionrevealed no significantdifferences in regional
wall motion between the two treatment groups at 8 weeks
after infarction. An additional limitation of the study is the
small number of patients in many of the subgroups, in par-
ticular the group randomized to treatment at less than 3
hours from the onset of symptoms.
The echocardiographic findings in this study are con-
cordant with the late global and regional radionuclide ejec-
tion fraction studies in the entire cohort of patients in the
Western Washington Intracoronary Streptokinase Trial (15),
which also failed to demonstrate any improvement in global
left ventricular function after streptokinase treatment. Fur-
thermore, the data are also in agreement with tomographic
thallium-201 measurements of infarct size, which showed
no difference between control patients and patients treated
with streptokinase (15).
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Left ventricular thrombus after streptokinase ther-
apy. This is the first randomized study to attempt to assess
whether streptokinase therapy reduced left ventricular
thrombus formation. In a preliminary report of a nonran-
domized study with no control group, Friedman et al. (22)
concluded that intracoronary streptokinase did not reduce
the incidence of left ventricular thrombus formation, since
they detected thrombus formation in 7 of 13 patients with
successful reperfusion after left anterior descending coro-
nary artery occlusion. In contrast, Eigler et aI. (23). in a
nonrandomized study, noted that only I of 12 patients with
acute anterior infarction receiving intravenous streptokinase
developed left ventricular thrombus compared with 7 of 10
control patients (p < 0.(05). Streptokinase may be expected
to reduce thrombus formation, either by a reduction in in-
farct size or possibly by a direct thrombolytic effect on
acutely formed thrombus. Cowley et al. (24) documented
that systemic fibrinolytic activity may be present for as long
as 24 to 48 hours after a short-term infusion of intracoronary
streptokinase.
Although the difference was not significant. all left ven-
tricular thrombi occurred in patients with acute anterior
myocardial infarction in the group treated with streptoki-
nase. In part, this may be explained by the somewhat greater
prevalence of acute anterior myocardial infarction in the
streptokinase-treated group compared with the control group
of patients who survived to be studied at 8 weeks (42 versus
26%, p = NS). Overall, the incidence of thrombus for-
mation was relatively low. Thrombus was noted in only
17% (5 of 29) of all patients with acute anterior infarction
in this series. Prior series of patients (25,26) studied earlier
after infarction have noted a 34% incidence of left ventric-
ular thrombus formation in patients with acute anterior in-
farction. The lower incidence in our study may be due to
the early anticoagulant therapy that all patients received or
to the relatively late time that echocardiograms were per-
formed. Left ventricular thrombus formation may resolve
spontaneously without anticoagulant therapy in the weeks
to months after myocardial infarction (25.26). In a recent
study of patients with left ventricular thrombus formation
(26) detected early after acute myocardial infarction, ap-
proximately 40% of patients, with or without chronic an-
ticoagulant treatment, had thrombus resolution when re-
studied more than 6 months later. Although there was no
control over anticoagulant treatment after hospital dis-
charge, similar proportions of control patients and patients
treated with streptokinase had long-term anticoagulant ther-
apy. Thus, it is reasonable to conclude from our data that
streptokinase therapy does not decrease the incidence of late
ventricular thrombus formation over that which can be
achieved with anticoagulant treatment alone.
Implications. The negative findings of our study con-
trast with the improvement in 30 day and 6 month mortality
in patients treated with streptokinase in the entire cohort of
250 patients enrolled in the Western Washington Intracor-
onary Streptokinase Trial (I). Even with inclusion of the
patients who died early (3 streptokinase-treated, 10 control)
as the worst rank in nonparametric analyses, there was no
apparent beneficial effect of streptokinase therapy on re-
gional wall motion or aneurysm or thrombus formation. The
cause of this discrepancy is unclear. One hypothesis is that
intracoronary streptokinase reduces infarct size in some pa-
tients with the largest infarcts, but has no benefit in the
majority of patients. In this study, the time delay until re-
perfusion may have been too long. Whatever the potential
early benefits of intracoronary streptokinase therapy, there
docs not appear to be a benefit in preserving left ventricular
function or in reducing left ventricular aneurysm or throm-
bus formation in 8 week survivors of acute myocardial
infarction.
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Appendix*
The principal investigators and their associates of the Western Wash-
ington Intracoronary Streptokinase Trial. J. Ward Kennedy. MD, Di-
rector, James L. Ritchie, MD, Co-Director. Kathryn B. Davis, PhD. In-
vestigator. James K. Fritz, MD. Investigator; Data Coordinating Center.
Kathryn B. Davis, PhD, Charles Maynard, MA, David Fray, BA; Policy
Board. Simeon Rubenstein, MD. Chairman. Paul B. Beeson. MD. Thomas
S. Inui, MD, Lloyd D. Fisher, PhD; Consultants. K. Lance Gould, MD.
Houston. Texas, William Ganz, MD, Los Angeles. California. Harold T.
Dodge, MD. Seattle, Washington, Robert A. Bruce. MD. Seattle, Wash-
ington, Marie Cowan. RN, PhD, Seattle, Washington; Technicians. Carol
Alcock. Ann Coleman, Kay Gaines; Nurses. Dec Erickson, RN, Kathleen
McFadden, RN.
Clinical Associates. Overlake Hospital. Bellevue. Washing/Oil: e.E.
Hansing*. K.M. Hynes. R.E. Haynes, D.B. Ferrin, J.S. Schneider.IT
Holder. (Ken Hyles. Randy Swartz)*; SI. Joseph Hospital. Bellingham.
washington: R.S. Trenouth. D.C. Brown. D.D. McAfee (Susan Harris);
Everett General Hospital. E..-erett, washington: J.P. Nolan. D.J. Stewart.
W.J. MacDonald. K.H. Prindle. N.D. Smith. J. Schmitt (Linda Woucha,
Harlan Jones); Providence Hospital, Smilie. wushington: G.A. Logan,
EM. Tohis. T.A. Block. J.G. Doccs, M.T. English. P.e. Albro, A.L.
Sytrnan. R.A. Crone. e.G. Hale. B. Green (Pat Jordan); Swedish Hospital.
Seattle. Washington: F.A. Short. W.E. Samson. R.J. Westcott. J.L. Pe-
terson (Linda Gorborino): Universitv Hospital. Seattle, washington: D.K.
Stewart. J.A. Murray. K.F. Hossack. J.A. Werner. G. Frank, G.B. Brown,
D.W. Weaver, G.B. Trobaugh (Royce Snyder); Veterans Administration
Medical Center. Seattle. Washington: J.W. Kennedy, J.L. Ritchie, l.H.
Caldwell. J. Stratton. (Carol Alcock); Virginia Mason Hospital. Seattle,
washington: R.R. Johnston (Mary A. Madsen); Madigan Arm." Hospital.
Tacoma. Washinf(lOn: J.L. Hill. T. Steudel. R. Chamusco (Don Felton,
Pearl C. Jakeman): Tacoma General Hospital. Tacoma. Washinf(lOll: E.
Lapin. 1. Reagan (John Viles); SI. Joseph's Hospital. Tacoma. Washin~
ton: J.R. McDonough. M. Henry (Tom Samon); Vancouver General Hos-
pital. Vancouver. British Columbia: R.R. Ricci; Wen{l/chee Valley Hos-
pital, Wenatchee. Washington: D. Larson. J. Gorham (Larry Keyser); St.
Elizabeth Hospital. Yakima. Washington: D.A. Monick , R.D. Twiss. A.B.
Preacher. R.K. Spiegel (Frances Braunagel. Mark Rupert).
*The physicians whose names arc underlined were administratively
responsible for the trial at their institutions. The catheterization laboratory
technicians responsible for the study are listed in parentheses.
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